News

Fujifilm Irvine Scientific Opens European Manufacturing Facility

December 09, 2021

Fujifilm’s new cell culture media manufacturing facility in the Netherlands has officially opened.

Crown Bioscience Expands In-Vivo Capacity at UK Facility

December 09, 2021

The additions to Crown Bioscience’s UK facility will increase and expand the company’s current in-vivo offering.

EU Approves Roche’s Treatment for Severe COVID-19

December 08, 2021

Roche’s Actemra/RoActemra (tocilizumab) is now approved in the EU for the treatment of adults with severe COVID-19 symptoms.

AstraZeneca Signs Blockbuster Deal With Ionis for TTR Amyloidosis Treatment

December 08, 2021

AstraZeneca struck a deal worth up to more than $3.5 billion with Ionis Pharmaceuticals for the rights to develop and commercialize their transthyretin (TTR) amyloidosis treatment.

FDA Grants Longeveron Orphan Drug Designation for Lomacel-B

December 08, 2021

Longeveron’s Lomacel-B received an Orphan Drug Designation for the treatment of Hypoplastic Left Heart Syndrome.

Salubrent Pharma Solutions Strengthens Analytical Team

December 08, 2021

Annad Padmanabhan and Maggie Thomasson will fill key roles at Salubrent’s new cGMP analytical laboratory in Kannapolis, NC.

Drug Costs Central Issue in Budget Battles

December 07, 2021

President Joe Biden highlighted how current proposals for curbing outlays on pharmaceuticals will help protect patients’ health and save the government billions.

Recordati Acquires EUSA Pharma for $845 Million

December 06, 2021

Recordati’s blockbuster acquisition of EUSA Pharma gives them access to a portfolio of four drugs that treat rare cancers.

FDA Panel Recommends Merck’s COVID-19 Pill

December 06, 2021

Following mixed results from clinical trials, a panel of outside experts voted 13-10 to recommend Merck’s pill for Emergency Use Authorization.

Rituximab Plus Chemotherapy Approved by FDA for Select Pediatric Cancers

December 03, 2021

Subtitle FDA approved rituximab in combination with chemotherapy for pediatric patients with previously untreated, advanced stage, CD20-positive DLBCL/BL/BLL/B-AL.